Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: A single-institution experience

Cancer

Volumn 112, Issue 3, 2008, Pages 572-580

  Plesa, Claudiu ^a   Chelghoum, Youcef ^a   Plesa, Adriana ^b   Elhamri, Mohamed ^a   Tigaud, Isabelle ^c   Michallet, Mauricette ^a   Dumontet, Charles ^b   Thomas, Xavier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Lyon Civil Hospices   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Acute myeloid leukemia; Chemotherapy; Cytogenetics; Immunophenotype; Prognosis

Indexed keywords

CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD13; ANTIGENS, CD15; ANTIGENS, CD34; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; BONE MARROW; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38849137937     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23219     Document Type: Article

References (34)

1. Mason KD, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev. 2006;20:71-82.
2. Griffin JD, Davis R, Nelson DA, et al. Use of surface marker analysis to predict outcome of adult acute myeloblasts leukemia. Blood. 1986;68:1232-1241.
3. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38:139-152.
4. Schwarzinger I, Valent P, Koller U, et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblasts leukemia. J Clin Oncol. 1990;8:423-430.
5. San Miguel JF, Ojeda E, Gonzalez M, et al. Prognostic value of immunological markers in acute myeloblastic leukemia. Leukemia. 1989;3:108-111.
6. Tucker J, Dorey E, Gregory WM, et al. Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. Hematol Oncol. 1990;8:47-58.
7. - phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia. 1992;6:393-399.
8. Campos L, Guyotat D, Archimbaud E, et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol. 1989;72:161-166.
9. Legrand O, Perrot J, Baudard Y, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96:870-877.
10. Bradstock K, Bishop J, Matthews J, et al. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood. 1994;84:1220-1225.
11. Tien HF, Wang CH, Lin MT, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet. 1995;84:60-68.
12. Chang H, Salma F, Yi Q, et al. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res. 2004;28:43-48.
13. Lauria F, Raspadori D, Ventura MA, et al. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic significance. Stem Cells. 1995;13:428-434.
14. Geller RB, Zahurak M, Hurwitz CA, et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem cell glycoprotein CD34 (My-10). Br J Haematol. 1990;76:340-347.
15. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia. 2000;14:480-487.
16. Estey E. How I treat older patients with AML. Blood. 2000;96:1670-1673.
17. Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia. 1999;13:1481-1490.
18. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
19. Johnson P, Hunt L, Liu Yin J. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol. 1993;85:300-306.
20. Wahlin A, Markevarn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol. 2001;115:25-33.
21. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323-3329.
22. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 and older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2006;106:1090-1098.
23. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
24. Gardin C, Turlure P, Fagot T, et al. Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy-results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129-5135.
25. Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106:27-34.
26. Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia. 1999;13:843-849.
27. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood. 1997;90:2952-2961.
28. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group. J Clin Oncol. 1998;16:872-881.
29. Thomas X, Suciu S, Rio B, et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica. 2007;92:389-396.
30. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia: review. J Clin Oncol. 1990;8:813-819.
31. Vercauteren S, Zapf R, Sutherland H. Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33. Cytotherapy. 2007;9:194-204.
32. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B8461. Blood. 2006;108:63-73.
33. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108:3280-3288.
34. Gupta V, Chun K, Yi QL, et al. Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer. 2005;103:2082-2090.